Recapping the Recently Completed Supreme Court Term: IP Decisions, Denials and Deferrals
Details
- Publish Date:
- August 14, 2023
- Author(s):
-
- Carey, Thomas
- Source:
- IPWatchdog
- Related Person(s):
- Related Organization(s):
Summary
The Supreme Court appeal attracted nearly three dozen amicus briefs. Not surprisingly, some major drug companies supported Amgen’s position. So did a slew of law professors headed by Mark Lemley, who argued that genus claims in life sciences should be allowed so that competitors would not be able to avoid them by making minor changes to the claimed chemical while “capturing the heart of the invention.”
Read More